BML-281

an HDAC6 inhibitor

Also Known As:

N-hydroxy-7-(5-(4-tert-butoxycarbonylaminophenyl)-3-isoxazolecarboxamido)heptanamide; N-hydroxy-7-(5-(4-tertbutoxycarbonylaminophenyl)-3-isoxazolecarboxamido)heptanamide

Networked: 2 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amines: 4871
  - Hydroxylamines: 16
    - Hydroxamic Acids: 239
      - BML-281: 2
- Carboxylic Acids: 973
  - Hydroxy Acids: 94
    - Hydroxamic Acids: 239
      - BML-281: 2
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Isoxazoles: 155
      - BML-281: 2

Experts

1.	Do, Anh: 1 article (01/2017)
2.	Fairlie, David P: 1 article (01/2017)
3.	Iyer, Abishek: 1 article (01/2017)
4.	Lohman, Rink-Jan: 1 article (01/2017)
5.	Reid, Robert C: 1 article (01/2017)
6.	Sweet, Matthew J: 1 article (01/2017)

Related Diseases

1.	Colitis 01/01/2017 - "Control and acute DSS-colitis mice were treated with BML-281 (1 mg/kg per day s.c. " 01/01/2017 - "Administration of BML-281 to DSS-treated mice attenuated colitis, weight loss, and disease pathology, including changes in colon structure and function, by eliciting broad-spectrum anti-inflammatory effects and preventing infiltration and activation of key immune cells in the lamina propria of the intestinal epithelium. " 01/01/2017 - "This study investigated whether treatment with a potent HDAC6 inhibitor, BML-281, could protect against colonic inflammation and prevent inflammatory cell infiltration into the colon to drive disease pathology in a mouse model of acute dextran sodium sulfate (DSS) colitis. " 09/28/2023 - "BML-281, an HDAC6 inhibitor, has been known to prevent tumors, acute dextran sodium sulfate-associated colitis, and lung injury. "
2.	Neuroblastoma 09/28/2023 - "In this study, we investigated the effect of BML-281 on neuroblastoma SH-SY5Y cell differentiation into mature neurons by immunocytochemistry (ICC), reverse transcriptase PCR (RT-PCR), quantitative PCR (qPCR), and western blotting analysis. "
3.	Inflammation (Inflammations) 01/01/2017 - "Some HDAC inhibitors are used in the clinic to treat cancer, and the results here for BML-281 highlight the potential for HDAC6 inhibitors to be used in a clinical setting for preventing and treating colonic inflammation and IBD in humans." 01/01/2017 - "This study investigated whether treatment with a potent HDAC6 inhibitor, BML-281, could protect against colonic inflammation and prevent inflammatory cell infiltration into the colon to drive disease pathology in a mouse model of acute dextran sodium sulfate (DSS) colitis. "
4.	Neoplasms (Cancer) 01/01/2017 - "Some HDAC inhibitors are used in the clinic to treat cancer, and the results here for BML-281 highlight the potential for HDAC6 inhibitors to be used in a clinical setting for preventing and treating colonic inflammation and IBD in humans." 09/28/2023 - "BML-281, an HDAC6 inhibitor, has been known to prevent tumors, acute dextran sodium sulfate-associated colitis, and lung injury. "
5.	Lung Injury 09/28/2023 - "BML-281, an HDAC6 inhibitor, has been known to prevent tumors, acute dextran sodium sulfate-associated colitis, and lung injury. "

Related Drugs and Biologics

1.	Dextrans (Dextran)
2.	sodium sulfate (sodium bisulfate)
3.	RNA-Directed DNA Polymerase (Reverse Transcriptase)
4.	Histone Deacetylase Inhibitors